Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-B2033 |
Synonyms | |
Therapy Description |
Limited information is currently available on BGB-B2033, a putative bispecific antibody targeting TNFRSF9 (4-1BB) and GPC3 (Oct 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-B2033 | BGB B2033|BGBB2033 | GPC3 Antibody 5 TNFRSF9 Antibody 32 | Limited information is currently available on BGB-B2033, a putative bispecific antibody targeting TNFRSF9 (4-1BB) and GPC3 (Oct 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06427941 | Phase I | BGB-B2033 BGB-B2033 + Tislelizumab | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | NZL | 1 |